Anzo

Quick links to important sections

Anzo

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anzo

Quick Facts: Anzo

Property Description
Active ingredient Lansoprazole
Form Oral (Delayed-Release Capsule, Orally Disintegrating Tablet, Powder for Oral Suspension)
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Sustained reduction of gastric acid output
Origin Synthetic compound (substituted benzimidazole)

What Type of Medicine is Anzo?

Anzo is a synthetic prescription medicine whose active component is Lansoprazole, a compound classified as a substituted benzimidazole. Its identity is rooted in its pharmacological class: the Proton Pump Inhibitor (PPI) group, a class of drugs that is clinically recognized for its high efficacy in addressing acid-related conditions. Its core function is to act as a potent Gastric Acid Secretion Inhibitor, intended to achieve a lasting reduction of stomach acid levels. Lansoprazole is effective in decreasing the amount of acid produced in the stomach.


Understanding Anzo's Composition and Purpose

The formulation of Anzo is specifically designed around the Lansoprazole molecule to ensure optimal delivery and effectiveness. It is prepared for oral ingestion in several forms, including the Delayed-Release Capsule and the Orally Disintegrating Tablet. The essential delayed-release characteristic is critical; it shields the active ingredient from the destructive stomach acid, allowing the drug to pass safely to the intestine for proper absorption. This systemic action allows the compound to reach the acid-producing cells and perform its function. By consistently and effectively suppressing gastric acid secretion, Anzo provides the general therapeutic benefit of maintaining low acidity, which is essential for managing conditions associated with high acid levels.

Regulatory References

  1. Lansoprazole: MedlinePlus Drug Information

What side effects are possible with Anzo?

Possible side effects and safety information

The safety profile of Anzo (Lansoprazole) is based on official classifications derived from clinical trials and post-marketing surveillance, as documented by governmental regulatory authorities. This information details the potential adverse reactions, their official frequency classifications, and necessary safety constraints.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions, classified as Common (ge 1% in clinical studies), primarily affect the Gastrointestinal disorders system-organ class. These include diarrhea, abdominal pain, nausea, and constipation. Common effects also extend to Nervous system disorders, such as headache and dizziness, and may involve an increase in liver enzyme levels.

Less frequently reported reactions, classified as Uncommon, include fatigue, specific changes in blood cell counts (e.g., thrombocytopenia), and skin effects such as rash and urticaria.

Documented Serious Adverse Reactions and Safety Constraints

Official prescribing information notes several serious adverse reactions and safety constraints, many of which are associated with prolonged exposure:

  • Bone Fracture Risk: Use for long durations (typically a year or longer) and/or at high doses may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine, particularly in the older population.
  • Hypomagnesemia: Severe hypomagnesemia (low serum magnesium) has been rarely reported with prolonged treatment, potentially manifesting with serious symptoms like ventricular arrhythmia.
  • Kidney and Gastrointestinal Events: Cases of Acute Tubulointerstitial Nephritis (TIN) and an increased risk of Clostridium difficile-Associated Diarrhea (CDAD) have been observed during therapy.
  • Gastric Malignancy: Symptomatic response to Anzo does not preclude the presence of gastric malignancy, a safety constraint documented in labeling.

Population-Specific Notes: Patients with moderate to severe hepatic impairment should be managed with caution and kept under regular supervision. The orally disintegrating tablet formulation contains phenylalanine, which is a safety consideration for individuals with phenylketonuria (PKU).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents on Anzo (Lansoprazole) outline required emergency actions and the specific limitations of medical intervention in an overdose situation. Data on acute overdose is limited; for example, one case involving the ingestion of a dose as high as 600 mg was documented to occur without any reported adverse effects or symptoms. Despite this limited toxicity profile, immediate professional guidance is strictly mandated by government health authorities.

Required Emergency Actions

Immediate medical attention must be sought in the event of a suspected or actual overdose of Anzo. Individuals must call the Poison Help line or contact a Poison Control Center right away, as specified in regulatory guidance.

Official Treatment Limitations

The medical management of an Anzo overdose is governed by specific facts documented in official labeling. A specific antidote is not available for Lansoprazole, and the drug cannot be significantly removed from the circulation by haemodialysis. Due to these factors, professional medical management is defined as symptomatic and supportive treatment. Procedural measures, such as gastric emptying and the use of charcoal, may be considered. These requirements establish that urgent external medical support is necessary for any potential overdose scenario.

Therapeutic Uses of Anzo

Therapeutic Indications and Mechanism of Action

Anzo is a pharmacological treatment primarily indicated for the management of clinical conditions associated with gastric acid hypersecretion. It belongs to the class of medications known as proton pump inhibitors (PPIs). These agents function by inhibiting the hydrogen-potassium adenosine triphosphatase (H^+/K^+-ATPase) enzyme system, commonly referred to as the gastric acid pump, located within the parietal cells of the stomach lining. By blocking this final stage of acid production, the medication effectively reduces the acidity of gastric secretions.

Primary Uses

  • Gastroesophageal Reflux Disease (GERD): It is used to treat symptomatic reflux, where gastric acid flows back into the esophagus, causing irritation and discomfort. It is also indicated for the healing of erosive esophagitis, which involves visible damage to the esophageal lining caused by chronic acid exposure.
  • Peptic Ulcer Disease: The medication is used in the treatment and prevention of gastric and duodenal ulcers. By reducing acid levels, it allows the mucosal lining of the stomach or small intestine to heal.
  • Zollinger-Ellison Syndrome: This treatment is utilized for pathological hypersecretory conditions where the stomach produces excessive amounts of acid.
  • NSAID-Associated Ulcer Prevention: It may be used to reduce the risk of developing gastric ulcers in patients who require long-term therapy with non-steroidal anti-inflammatory drugs.

Therapeutic Benefits

Reducing gastric acid production provides several clinical benefits focused on mucosal recovery and symptom management:

  • Symptom Relief: Effective reduction of acid levels typically leads to a decrease in symptoms such as heartburn and acid regurgitation.
  • Tissue Healing: Lowering the acidity of the gastric environment creates an optimal condition for the repair of damaged esophageal and gastric tissues.
  • Maintenance of Remission: Continued use in specific cases can help prevent the recurrence of inflammation or ulceration in the upper gastrointestinal tract.

Regulatory References

  1. NIH MedlinePlus Drug Information on Lansoprazole

Eligibility and Restrictions for Use

Who Can and Cannot Use Anzo?

This section details the official population-eligibility and non-eligibility rules for Anzo (Lansoprazole), based strictly on government regulatory documents.


Absolute Contraindications

Anzo must not be used by individuals who have a known hypersensitivity or severe allergic reaction to Lansoprazole or any of the product's components. Use is also absolutely prohibited if the patient is taking specific anti-retroviral medications, such as rilpivirine or nelfinavir, as this combination risks rendering the HIV treatment ineffective

. Specific oral formulations containing sucrose are contraindicated in patients with rare hereditary fructose intolerance or related glucose-galactose malabsorption disorders.


Age-Based Eligibility and Restrictions

Population Group Eligibility Status
Adults (18+ years) Generally Approved for all labeled indications.
Pediatric (1–17 years) Approved for short-term treatment of symptomatic GERD and erosive esophagitis.
Infants (< 1 year) Use Not Recommended; efficacy was not demonstrated for symptomatic GERD in this age group.

Conditional Use

Patients with severe hepatic impairment (liver disease) require caution, and regulatory guidelines mandate that a dosage restriction is necessary due to the drug's reduced clearance in this population. For patients with renal impairment, no dosage adjustment is typically required. Its use during pregnancy and breastfeeding is considered conditional, requiring the benefit to be weighed against the potential risk, as its status is not definitively established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug interactions with Anzo (Lansoprazole), a Proton Pump Inhibitor, primarily resulting from its effect of altering gastric pH or its influence on metabolic enzymes.

Interaction Classifications

Classification Substance / Combination Official Regulatory Outcome
Contraindicated Atazanavir, Nelfinavir, Rilpivirine Co-administration is prohibited due to the risk of significantly decreased plasma levels of the antiviral agents.
Increased Exposure Digoxin, Tacrolimus, Methotrexate Lansoprazole increases plasma concentrations, potentially prolonging exposure; requires careful monitoring.
Decreased Exposure Ketoconazole, Itraconazole, Ampicillin Esters Lansoprazole reduces the absorption and bioavailability of these agents by changing the gastric pH.
Reduced Efficacy Clopidogrel May result in reduced efficacy due to altered formation of the antiplatelet's active metabolite.

Timing and Monitoring Constraints

Regulatory sources define mandatory conditions for co-administration. Co-treatment with Warfarin (and other coumarin anticoagulants) requires close monitoring for increases in the International Normalized Ratio (INR) and prothrombin time. Administration of Sucralfate must be separated from Lansoprazole by at least 30 minutes to prevent interference with absorption. Additionally, the regulatory profile notes that the interaction effects may be increased in patients with severe hepatic impairment due to the drug’s slower removal from the body.

Mechanism of Action

Irreversible Blockade of the H^+/ K^+- ATPase

Anzo (Lansoprazole) acts as a specific prodrug, requiring acid activation within the highly acidic secretory canaliculus of the gastric parietal cell. Upon activation, it transforms into an irreversible inhibitor that forms covalent bonds with cysteine residues on the H^+/ K^+- ATPase enzyme (Proton Pump) . This chemical binding permanently deactivates the enzyme responsible for the final step of acid secretion, resulting in a physiological elevation of intragastric pH.

⏱️ Mechanism Duration Governed by Enzyme Synthesis

The drug's sustained physiological effect is due to this irreversible action. Since the blocked enzymes must be replaced through new synthesis by the parietal cell, and this process is slow, the binding translates to a long biological blockade of the secretory process, enabling durable, 24-hour modulation of the gastric environment. This mechanism is constrained to only inhibit pumps that are actively functional and exposed, reflecting a high degree of mechanistic specificity.

Dosage and Administration Information

How to Use Anzo

Anzo (Phenazopyridine Hydrochloride) is an analgesic drug used to relieve symptoms associated with urinary tract irritation, such as pain, burning, urgency, and frequency. It should only be used to relieve symptoms and does not treat the underlying cause of infection. Consultation with a healthcare provider is essential for a diagnosis and prescription to treat the infection.

Administration and Dosage

Population Dosage Administration Details
Adults and Children 12 years and older Two (2) tablets three (3) times daily Take with a full glass of water, with or after meals to help reduce stomach upset.
Children under 12 Do not use Consult a doctor before use.

It is generally advised not to use Anzo for more than two days (12 tablets) without consulting a physician. The typical recommended treatment duration is 2 days, providing relief until antibiotic therapy can take effect. Prolonged use should be avoided unless directed by a healthcare professional.

Important Safety Information

  • Urine Color Change: The medication will cause urine to turn a reddish-orange color. This is not harmful, but caution should be used to avoid staining clothing or contact lenses.
  • Stomach Upset: Taking Anzo with or after meals may help minimize gastrointestinal discomfort.
  • Interference with Tests: Anzo can interfere with certain laboratory tests, including those for urine, glucose (sugar), and ketones.
  • When to Stop: Discontinue use and seek medical attention if symptoms persist for more than two days or if you suspect an adverse reaction to the medication.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Anzo (Lansoprazole)


Evidence for Healing Erosive Esophagitis and Ulcers

Research has been studied for conditions involving high gastric acid levels, specifically erosive esophagitis (EE) and gastric or duodenal ulcers. The core evidence comes from numerous short-term Randomized Controlled Trials (RCTs) and systematic reviews that evaluated patients with confirmed erosive damage and various ulcer types, comparing the measured outcomes to placebo or other acid-reducing medicines.

For the healing of EE, research monitored the rate at which the inner lining of the esophagus healed, typically over a period of up to 12 weeks. Findings describe patterns observed in the studies where groups using Anzo was associated with higher measured healing rates and a greater proportion of reported symptom-free days compared to placebo groups. Similarly, the healing of ulcers was evaluated in studies that reported measurements of the percentage of ulcers achieved within 4 to 8 weeks. Research highlights changes measured during the study period; findings contribute to understanding patterns related to the healing of these lesions.


Evidence for Long-Term Prevention and Maintenance

Beyond acute healing, research has focused on the long-term patterns of Anzo's use in reducing the measured rate of recurrence of certain conditions. This evidence was studied for maintenance therapy following the successful healing of erosive esophagitis. Studies for this purpose often used longer RCTs extending up to 12 months, where researchers monitored whether the healed esophageal lining remained stable (preventing relapse) or if symptoms returned.

Research also examined the role of Anzo in reducing the measured incidence of ulcers for individuals who must take Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) continuously. These studies tracked the cumulative incidence of new ulcers in this high-risk population. Data show patterns related to a lower measured incidence of these ulcers over a period of up to 12 months, indicating the research profile is relevant for scenarios requiring prophylactic study.


Studies for Conditions Requiring Continuous Acid Control

Anzo was evaluated in settings involving pathological hypersecretion of stomach acid, such as Zollinger-Ellison Syndrome (ZES). Due to the rarity of the disease, the research was studied for this condition primarily through long-term prospective cohort studies rather than large-scale RCTs.

In these observational settings, research examined outcomes related to systemic or functional imbalance by monitoring the measured control of gastric acid output below a defined therapeutic threshold. Findings describe patterns where continuous administration was associated with observations of sustained acid level measurements and the healing of associated ulcers over several years of observation. The main limitation here is that the sample sizes were modest in the cohorts studied due to the rarity of ZES.

Key Studies & References

  1. Lansoprazole: MedlinePlus Drug Information
  2. PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE Scientific discussion Lansoprazole 15 mg & 30 mg Gastro-resis (HPRA/EMA)

Frequently Asked Questions (FAQ)

Common questions about Anzo (FAQ)


Q: What's the difference between Anzo and other similar medications I see advertised?

A: Anzo is classified as a Proton Pump Inhibitor (PPI), a specific type of medicine used to reduce stomach acid. Official sources describe its action as forming an irreversible bond with the enzyme responsible for the final stage of acid production. This specific mechanistic profile is a key aspect of how it works.


Q: Can older adults typically use Anzo?

A: Regulatory documents state that adults, including older adults, are generally approved for the labeled uses of Anzo. However, there is a documented safety constraint that prolonged use (typically a year or longer) may be associated with an increased risk of osteoporosis-related fractures (weakened bone breaks), particularly in the older population.


Q: Is Anzo approved in other countries besides the U.S.?

A: Yes, the active ingredient in Anzo, lansoprazole, has product information documented by multiple governmental and intergovernmental regulatory bodies across the world, including those in Europe (referenced by the EMA). This indicates its regulatory status extends beyond the U.S. market.


Q: What should I do if I think I'm experiencing a serious side effect from Anzo?

A: Official product labeling advises seeking immediate care from a healthcare professional for symptoms that do not improve or if you suspect you are experiencing a serious adverse reaction. Serious adverse reactions are described in detail within the full safety information provided by regulatory agencies.


Q: What is the general success rate mentioned in the clinical trials for Anzo?

A: Research evidence describes study patterns where groups using Anzo were associated with higher measured healing rates and a greater proportion of reported symptom-free days compared to placebo groups in acute healing studies. This research profile supports its use in managing acid-related conditions.


Q: Can Anzo be crushed or split in half?

A: No, the delayed-release capsule form of Anzo must be swallowed whole. Official instructions state not to crush or chew the capsules. This is because the capsule is specifically designed with a coating to protect the medicine from destructive stomach acid, allowing for proper absorption further down in the digestive system.


Q: Is Anzo the same as [Name of a similar, common drug]?

A: Anzo is the brand name for the active ingredient lansoprazole. It belongs to the class of medicines known as Proton Pump Inhibitors (PPIs). While there are other PPIs, regulatory information identifies Anzo by its unique active ingredient and specific formulation.


Q: Will Anzo change the results of blood tests?

A: Official safety information notes that use of Anzo can be associated with specific changes that may be detected in blood tests, including an increase in liver enzyme levels and certain changes in blood cell counts. Additionally, prolonged use may be associated with low serum magnesium (Hypomagnesemia).


Q: What is the shelf life of Anzo tablets?

A: Anzo should be stored at Controlled Room Temperature, which is generally between 20 C and 25 C (68 F to 77 F). If the medicine is supplied in a bottle, the regulatory shelf life after it has been opened for the first time is three months, provided the container is kept tightly closed and protected from moisture.


Q: Are there specific symptoms that mean I should stop taking Anzo?

A: Regulatory warnings advise discontinuing the medicine and seeking further evaluation if signs or symptoms of severe cutaneous adverse reactions (severe skin effects), other signs of hypersensitivity (a serious allergic reaction), or a kidney condition known as Acute Tubulointerstitial Nephritis occur.


Q: How quickly does Anzo start working?

A: Official product information indicates that it may take one to four days for the full effect to be observed, meaning a change in acid levels. However, relief of symptoms may be experienced by some patients within the first 24 hours of starting treatment.


Q: Does Anzo interact with common pain relievers like Tylenol (acetaminophen)?

A: Official regulatory interaction classifications have noted no known interaction between Anzo (lansoprazole) and the common over-the-counter pain reliever acetaminophen. However, it is always advised to inform your healthcare provider about all medicines you are taking.


Q: Are there any major food or drink restrictions while taking Anzo?

A: Regulatory guidance for administration typically advises taking the medicine before meals to ensure proper absorption. No specific major food restrictions are listed, but taking it after meals can reduce its absorption. Please note that official directions advise against taking it with alcohol.


Q: What happens if I miss a scheduled dose of Anzo?

A: Regulatory instructions for a missed dose indicate the following sequence: if remembered soon after, the dose may be taken. If it is almost time for the next scheduled dose, the instruction indicates that the missed dose should be skipped to resume the regular schedule. Doses should not be doubled.


Q: Are there any known issues with taking Anzo and alcohol?

A: Yes. The official directions for Anzo contain a clear safety statement that the medicine should not be taken with alcohol.


Q: Does Anzo have any interactions with herbal supplements like St. John's Wort?

A: Official patient guidance advises disclosing the use of all herbs, non-prescription drugs, and dietary supplements to a healthcare provider as some items may interact with the way the medicine is absorbed or metabolized by the body.


Q: Will Anzo make me gain or lose weight?

A: Weight change is not listed as a common or uncommon side effect in the official safety profile. However, official safety information notes that symptoms that could be related to severe adverse reactions (such as unusual weight gain related to swelling or edema) have been observed and require immediate consultation.


Q: Is there a generic version of Anzo available?

A: Yes, Anzo is the brand name for the generic compound lansoprazole. Regulatory documents often refer to the medicine by its generic name, which is widely available.


Q: Can Anzo affect my ability to drive or operate machinery?

A: Official safety information lists common side effects such as dizziness and less common side effects such as fatigue. Patients are advised to be aware of how they react to the medicine before deciding to drive or operate complex machinery.


Q: How is Anzo usually taken—with or without food?

A: The delayed-release form of Anzo is typically administered before a meal (e.g., before breakfast) to ensure optimal absorption and effectiveness. This is a key part of the administration instructions outlined in the official product information.


Q: Does taking Anzo with milk change how it works?

A: The official prescribing information details specific types of soft food (like applesauce or yogurt) and juices (like apple juice) that can be used for administration if the capsule is opened. Milk is not included in the list of approved vehicles for administration.


Q: Does Anzo have a risk of addiction or dependency?

A: No. Anzo is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). The DEA Schedule for the drug is listed as 'None', meaning it has no regulatory association with addiction or dependency risk.


Q: Are there any common over-the-counter medicines to avoid while on Anzo?

A: Official documentation advises reporting all over-the-counter medicines to a healthcare provider, as some can interfere with absorption or create interactions. While interaction analysis has noted no known interaction with acetaminophen, other medications can interfere with absorption or create interactions. The safest approach is to ensure a healthcare professional is aware of all medicines being taken for advice on combination use.


Q: Does Anzo interact with vitamin supplements?

A: Official safety information notes that daily long-term use (e.g., longer than three years) may lead to reduced absorption or a deficiency of Vitamin B12. The safety information advises consulting a healthcare professional to manage potential Vitamin B12 concerns during treatment.


Q: Why would a doctor prescribe Anzo over other options?

A: Anzo is described as a Proton Pump Inhibitor that acts as an irreversible inhibitor of the enzyme responsible for final acid secretion. Regulatory-supported research has examined its use for the healing and long-term prevention of specific acid-related conditions like erosive esophagitis, which informs its place in treatment options.


Q: Is it better to take Anzo in the morning or at night?

A: Official administration instructions advise taking the delayed-release capsule before eating in the morning (before breakfast). This timing is recommended to achieve optimal results by targeting the acid-producing cells when they are most active.

How should Anzo be stored and disposed of?

The storage and disposal instructions for Anzo (lansoprazole) are established to protect the integrity of the delayed-release formulation.

Official Storage Requirements

Anzo must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from moisture and must remain in its original package. If supplied in a bottle, the container must be kept tightly closed; the shelf life after first opening is three months.

All forms of Anzo must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Anzo should be discarded using an official drug take-back program. If a program is unavailable, the medicine is not on the flush list and must be mixed with an unappealing substance, placed in a sealed container, and thrown into the household trash. Disposal of waste material must be in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Anzo found in:

A-Z Index: